Company Registration No. 12635230 (England and Wales)
CX PHARMA CONSULTING LIMITED
Annual Report and Statement of Accounts
For the Period from 01 June 2025 to 31 May 2026

CX PHARMA CONSULTING LIMITED

Annual report and statement of accounts for the period ending 31/05/2026

CX PHARMA CONSULTING LIMITED

Financial statement for the period ended 31/05/2026

Company Information

1 Statutory Information
Company Number 12635230
Registered Office JESTERS MAIN ROAD SWALCLIFFE
BANBURY
OX15 5EH
2 Directors
Directors who held office during the period were:
Matthew James STANTON   
3 Principal Activity
Marketing campaigns
4 Employees
Average number of employees, including directors, during the year was as follows:
2026 0
2025 0

CX PHARMA CONSULTING LIMITED

Financial statement for the period ended 31/05/2026

Statement of Financial Position

2026 2025
£ £
Fixed Assets 3,423 4,564
Current Assets 21,369 1,683
Creditors: amounts falling due within one year (14,508) (11,650)
Net Current Assets 6,861 (9,967)
Total assets less current liabilities 10,284 (5,403)
Creditors: amounts falling due after one year - -
Net Assets 10,284 (5,403)
Capital and reserves 10,284 (5,403)
For the period ending 31/05/2026 the company was entitled to exemption under section 477 of the Companies Act 2006 relating to small companies.
The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The Directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
These accounts have been prepared in accordance with the micro-entity provisions and delivered in accordance with the provisions applicable to companies subject to the small companies regime.
Approved by the Board on 10 July 2026
Matthew Stanton
Company Registration No. 12635230